Original Article

Advantage of early liver transplantation whenever indicated for hepatocellular carcinoma recurrence after primary liver resection

Kun-Ming Chan a,b,*, Tsung-Han Wu a,b, Chih-Hsien Cheng a,b, Chen-Fang Lee a,b, Ting-Jung Wu a,b, Hong-Shiue Chou a,b, Wei-Chen Lee a,b

a Department of General Surgery & Department of Organs Transplantation Institute, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
b College of Medicine, Chang Gung University, Taoyuan, Taiwan

A R T I C L E   I N F O

Article history:
Received 17 July 2018
Accepted 9 April 2019
Available online 29 October 2019

Keywords:
Hepatocellular carcinoma
Liver resection
Liver transplantation
Recurrence
Outcome

A B S T R A C T

Background: Liver transplantation (LT) for recurrent hepatocellular carcinoma (HCC) following liver resection (LR) has been considered a promising strategy for improving patient's outcome. The study aimed to analyse patients from primary LR to LT for HCC and to provide additional information for decision-making in therapeutic strategies for patients with HCC.

Methods: Among 776 LTs, a retrospective analysis of patients who had undergone LT for recurrent HCC after primary LR between May 2005 and 2017 February was performed.

Results: During the follow-up period, the overall recurrence-free survival rates at 1, 3 and 5 years were 84.8%, 68.2% and 68.2%, and disease-specific overall-survival rates were 95.7%, 74.4% and 66.7% at 1, 3 and 5 years after LT, respectively. Beyond University of California at San Francisco (UCSF) transplantation criteria (p = 0.018, hazard ratio (HR) = 12.70), maximum tumor size ≥ 5 cm at LR (p = 0.012, HR = 7.90) and period between post-LR HCC recurrence and LT ≥ 1 year (p = 0.030, HR = 7.57) were prognostic factors of HCC recurrence after LT. Moreover, HCC recurrence after LT was the solely independent risk factor affecting overall survival of patients.

Conclusion: Large tumor size at LR should be taken into cautious tending to HCC recurrence even after salvage LT. Importantly, LT should be considered as soon as possible preferably within 1 year whenever post-LR recurrent HCC meets transplantation criteria.

Hepatocellular carcinoma (HCC) is one of the most common malignancy and leading cause of cancer-related deaths worldwide. Despite rapidly evolving treatment for HCC, surgical management remains the main option for curative-intent therapy as well as offering the most favourable long-term outcomes [1–4]. Of these, surgical management consists of liver resection (LR) and liver transplantation (LT), and each has its advantages and disadvantages. To our
knowledge, LR has a higher incidence of cancer recurrence and an inferior survival rate as compared with LT [5–7]. Whereas, LT needs to fight against the shortage of organ availability and life-long immunosuppressant medication. Although selection of either LR or LT for early stage HCC is still a debatable option, the combination of LR followed by LT for late stage liver cirrhosis and/or recurrent HCC has been considered a promising strategy for patients with HCC [8,9].

As a result of improvements in surgical technique and perioperative patient care utilized for LT, it has now become a common and routine operation as foretold by Thomas E. Starzl a few decades ago. Recently, the concept of salvage LT for recurrent HCC after primary LR has been proposed to extend survival time of patients with HCC [8]. Subsequently, numerous experiences regarding the success of salvage LT were widely reported [10–13]. However, studies of outcome and HCC recurrence following LT remain entirely elusive. Moreover, despite a growing experience, predictors related to salvage LT is still an issue of great importance in order to optimise therapeutic strategies for patients with HCC. In the current study, we retrospectively reviewed our experience in patients who had undergone LT for recurrent HCC after primary LR. The study also aimed to examine factors associated with the prognosis and outcome of patients and to provide additional information for decision-making in therapeutic strategies for patients with HCC.

Materials and methods

Patients

A total of 776 consecutive LTs were performed at our institute between May 2005 and February 2017. All medical records of patients were retrospectively reviewed under the approval from the Institutional Review Board. Patients who had undergone LT for post-LR recurrent HCC were enrolled in the current study. As a result, 59 patients including 51 males and 8 females were eligible for analysis of this study. Meanwhile, 590 patients who had HCC recurrence following primary LR during the corresponding period were analysed for survival comparison as well.

Diagnosis and treatment of HCC

Clinically, the diagnosis of HCC was usually based on the diagnostic criteria of the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). The treatment of HCC mainly consisted of multidisciplinary therapy, including surgical management, locoregional therapies, radiation therapy and systemic chemotherapy or a combination of these treatments. Generally, the selection of treatment modality was determined by the consensus of the institute’s liver cancer committee, and LR was always the preferred treatment whenever HCC was considered to be resectable, as previously described [14].

LT was recommended for patients who had advanced liver cirrhosis and/or unresectable HCC, but patients with imaging evidence of extrahepatic metastasis or major vascular invasion were considered unsuitable for LT. HCC patients were placed on the waitlist only if imaging evidence of tumor status met the proposed criteria from the University of California at San Francisco (UCSF) [3] and in patients up to 70 years old. After LT, the explanted liver were thoroughly examined to determine the pathologic characteristics of HCC. All statistical analysis of variables regarding tumor characteristics were performed according to the pathological examination of the hepatic specimens obtained from LR and LT in this study.

Postoperative follow-up

Generally, the surveillance of patients after operation was similar for LR and LT. All patients were regularly followed for HCC recurrence by measurement of serum α-fetoprotein (AFP) and liver ultrasonography at monthly intervals in the initial 3 months and every 3 months thereafter until death or the end of the present study. Radiologic examinations including computed tomography (CT) and/or magnetic resonance imaging (MRI), were performed annually or whenever suspicious of HCC recurrence in patients after LR. However, radiologic imaging was routinely arranged at 3, 6, 12 months and every year afterward following LT.

Statistical analysis

The primary variables, including demographics and clinicopathologic features of LR and LT, were assessed to determine the prognostic factors. The Cox proportional hazards regression model was applied to identify the factors that influence HCC recurrence after LT, and all the significant factors with a p value of less than 0.1 from univariate analysis were further analysed by multivariate analysis in a forward stepwise manner. Recurrence-free survival (RFS) was defined by the date of LT or LR to the date of detecting HCC recurrence. Overall survival (OS) was measured from the date of LR or LT to the date of death or until the end of this study. Survival curves were constructed by the Kaplan–Meier method and further compared by the log rank test. All the data were analysed using the statistical software SPSS version 20.0 (IBM Inc.),
Results

Clinical features of patients

The clinical features of the patients with primary LR for HCC followed by LT are summarized in [Table 1]. Hepatitis B virus-related cirrhosis and HCC remain the main etiology of patients that accounted for 81.4% in this study. With regard to primary LR, the majority of patients had a single tumor (86.4%) and underwent LR less than 3 Couinaud’s segments (76.3%). Six patients underwent LR twice due to HCC recurrence after the first LR. The median time from the last LR to LT was 44.2 months (range 3.5–180.6 months), and the median period of post-LR HCC recurrence to LT was 11.0 months (range 1.0–174.0 months). Before LT, locoregional therapy was performed for post-LR recurrent HCC in 51 patients that consisted of 46 patients for bridging therapy and 5 for down-staging intent. Overall, 47 patients received living donor LT (LDLT), and 12 patients underwent deceased donor LT (DDLT). Based on pathological examination of hepatic specimens, 13 patients had HCC beyond UCSF transplantation criteria. There were 3 cases (5%) of hospital mortality within 3 months after LT, and 15 out of the remaining 56 patients (26.8%) experienced HCC recurrence after LT. By the end of this study, 39 patients (66.1%) were still alive, and 3 of them were alive with recurrent HCC. Additionally, twelve patients (20.3%) were dead of recurrent HCC, and 5 patients (8.5%) were dead because of diseases other than HCC.

Outcomes of patients

After LT, the median follow-up period for all patients was 29.0 months, ranging from 0.4 to 149.0 months. During the follow-

---

### Table 1 Clinicopathologic characteristics of patients.

| Characteristics                              | No. of patient (%) |
|----------------------------------------------|--------------------|
| Sex (Male:Female)                            | 51:8               |
| Hepatitis status                             |                    |
| Hepatitis B positive                         | 48 (81.4%)         |
| Hepatitis C positive                         | 6 (10.2%)          |
| Non-B and Non-C                              | 5 (8.4%)           |
| Primary liver resection                      |                    |
| Age at LR (years), median (range)            | 50 (26–68)         |
| Tumor nodule                                 |                    |
| Single                                       | 51 (86.4%)         |
| Multiple                                     | 8 (13.6%)          |
| Maximum tumor size, median (range)           | 2.5 (1.0–10.0)     |
| Extent of liver resection                    |                    |
| ≥3 segment                                   | 14 (23.7%)         |
| <3 segment                                   | 45 (76.3%)         |
| Period of LR to LT (months), median (range)  | 44.2 (3.5–180.6)   |
| Period of post-LR HCC recurrence to LT (months) | 11.0 (1.0–174.0) |
| Locoregional therapy before LT               |                    |
| Yes                                          |                    |
| Bridging therapy                             | 46 (78.0%)         |
| Down-staging intent                          | 5 (8.4%)           |
| No                                           | 8 (13.6%)          |
| Liver transplantation                        |                    |
| Age at LT (years), median (range)            | 54 (32–68)         |
| MELD score, median (range)                   | 9 (5–28)           |
| AFP (ng/ml), median (range)                  | 13.9 (1.3–2181)    |
| Type of LT                                   |                    |
| DDLT                                         | 12 (20.3%)         |
| LDLT                                         | 47 (79.7%)         |
| Pathologic tumor characteristics             |                    |
| Tumor Number, median (range)                 | 2 (1–29)           |
| Maximum tumor size, median (range)           | 2 (1.0–8.3)        |
| UCSF criteria (within:beyond)                | 46:13              |
| HCC recurrence                               | 15 (25.4%)         |
| Outcomes                                     |                    |
| Alive and HCC free                           | 36 (61.0%)         |
| Alive with recurrent HCC                     | 3 (5.1%)           |
| Died of HCC                                  | 12 (20.3%)         |
| Died of other causes                         | 5 (8.5%)           |
| Hospital Mortality                           | 3 (5.1%)           |

Abbreviations: LR: liver resection; HCC: hepatocellular carcinoma; LT: liver transplantation; MELD: Model for End-stage Liver Disease; AFP: alpha-fetoprotein; DDLT: deceased donor liver transplantation; LDLT: living donor liver transplantation.
The prognostic factors affecting HCC recurrence after LT were further examined from the clinicopathologic features of patients related to LR and LT, and are summarized in [Table 2]. Univariate analysis identified 7 significant factors including, maximum tumor size ≥5 cm at primary LR, extent of LR ≥ 3 segments, period between post-LR HCC recurrence and LT ≥ 1 year, tumor number >3 nodules at LT, maximum tumor size >3 cm at LT, presence of microvascular invasion at LT and beyond UCSF transplantation criteria. Furthermore, multivariate regression analysis of the aforementioned factors showed only 3 independent risk factors affecting HCC recurrence after LT. In addition to beyond UCSF transplantation criteria (p = 0.018, hazard ratio (HR) = 12.70), maximum tumor size ≥ 5 cm at LR (p = 0.012, HR = 7.90) and period between post-LR HCC recurrence and LT ≥ 1 year (p = 0.030, HR = 7.57) were independent prognostic factors of HCC recurrence following LT in this study.

Similarly, [Table 3] summarized univariate and multivariate analysis of prognostic factors affecting OS after LT. Although univariate analysis identified 5 significant factors, multivariate regression analysis showed HCC recurrence after LT (p = 0.012, HR = 5.45) was the only independent risk factor affecting OS after LT.

**Patient’s outcome driven by prognostic factors**

The influence of each prognostic factor on the outcomes of patients, in terms of RFS, is illustrated in [Fig. 3]. Patients with HCC that met the UCSF criteria had reasonably better RFS than those beyond UCSF criteria, in which the 3-year RFS rates were 86.0% versus 13.8%, respectively [Fig. 3A, p < 0.0001]. The 5-year RFS rate for patients who had maximum tumor size ≥5 cm at initial LR was only 35.9% as compared with the opposite group that enjoyed a better 5-year RFS rate of 80.2% [Fig. 3B, p = 0.006] Most importantly, a shorter duration between post-LR HCC recurrence and LT had a better RFS curve than that of a duration beyond 1 year. The 5-year RFS rates were 87.7% versus 44.4%, respectively [Fig. 3C, p = 0.001].

In order to clarify the significance of waiting time, multiple cutoffs for duration between post-LR HCC recurrence and LT were further evaluated using Akaike information criterion (AIC) that lower values indicate better model fit [Table 4]. As a result, the waiting period between post-LR HCC recurrence and LT beyond 12 months was confirmed as a significant prognostic factor for HCC recurrence after salvage LT.

**Discussion**

Nowadays, LR is without a doubt offering potential curative therapy available to treat patients with HCC [15–17]. Nonetheless, LR for patients with HCC is mainly frustrated by the estimated less than 30% of resection rate and high incidence of postoperative recurrence that could reach almost 70% at 5 years [18–20]. Apart from that, the ratio of patients with recurrent HCC eligible for repeat LR is very low as well [21,22]. Accordingly, salvage LT has now become the most promising strategy for these patients, which not only eradicates
intrahepatic recurrence of HCC but also cures the concurrent cirrhotic liver disease that impedes repeat LR. However, considering the severe organ shortage as well as high cost and risk of this procedure, individualised implementation of current multimodality treatment might be more efficient to prolong patient survival time. Based on this study, the study attempted to identify prognostic factors for patients undergoing LT after LR for HCC and demonstrated that patient outcome is significantly affected by the timing of LT following post-LR HCC recurrence.

The present study evaluated predictors of salvage LT strategy amongst those factors available starting from initial LR to enable an estimation of patient outcome. This was in contrast to most other previous studies where predictors of HCC recurrence after LT were merely identified based on the clinical characteristics of LT. According to our data, HCC featured by maximum tumor size ≥5 cm at initial LR and beyond UCSF transplantation criteria at LT were independent prognostic factors of HCC recurrence after LT. Importantly, maximum tumor size ≥5 cm has been previously identified as a risk factor of HCC recurrence after LR [16,23], indicating that advanced HCC would affect patient outcome not only in initial LR but also in LT for recurrent HCC afterwards.

However, the presence of microvascular invasion has been an important prognostic factor of LT for HCC in previous studies [24–26], but it was not an independent predictor for outcome in the end result of the current study. Numerous studies have reported that greater tumor burden in terms of size and number is associated with a greater chance of microvascular invasion [27,28]. Nonetheless, the present study might be limited by its small patient number and unable to explain the observation that microvascular invasion was not identified as a significant predictor. Additionally, unexplored factors may possibly play a principal role leading to HCC recurrence after LT, and a larger cohort study may be able to clarify this issue in the future.

Interestingly, the observation of inferior outcomes after LT related to the time period between post-LR HCC recurrence and LT beyond 12 months is noteworthy in this study. Similarly, a recent multicentre study showed an association between long waiting time (>18 months) and an increased risk for HCC recurrence after LT [29]. Indeed, a longer waiting period might still lead to tumor progression and possibly dropout of patients from the LT waiting list. However, the shortage of donor availability is always an unsolvable concern, especially from Asian countries where donor livers are scarce and the list of patients awaiting LT continues to grow [30]. Hence, LDLT might be an alternative strategy to increase donor availability and to shorten the timeframe of awaiting LT for HCC patients, and early transplantation for such patients should be encouraged.
Currently, LT has been considered the best therapeutic option for patients who have liver cirrhosis associated with HCC but are ineligible for liver resection. However, HCC recurrence after LT remains a major concern that accounted for 10–20% of patients in most reports of primary LT. The importance of HCC recurrence after LT was also reflected by the present study, in which it was the solely independent risk factors affecting overall survival of patients. Therefore, prevention of HCC

| Factors (patient number) | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|----------------------|
|                          | HR                  | 95% CI | p value | HR (95% CI) | p value |
| Sex (male, female) (51 vs. 8) | 0.95 | 0.27–3.27 | 0.940 | – | – |
| Hepatitis B virus (positive, negative) (48 vs. 11) | 0.77 | 0.25–2.32 | 0.644 | – | – |
| Hepatitis C virus (positive, negative) (6 vs. 53) | 1.19 | 0.27–5.18 | 0.808 | – | – |
| Liver resection | | | | | |
| Maximum tumor size (≥5, < 5 cm) (16 vs. 43) | 3.34 | 1.37–8.12 | 0.008 | 1.97 (0.63–6.15) | 0.238 |
| Extent of LR (≥3, ≤3 segments) (14 vs. 45) | 3.11 | 1.28–7.55 | 0.012 | 1.36 (0.39–4.74) | 0.627 |
| Recurrent time after LR (≥1, < 1 year) (42 vs. 17) | 0.87 | 0.33–2.29 | 0.786 | – | – |
| HCC recurrence to LT (≥1, < 1 year) (26 vs. 33) | 1.96 | 0.80–4.81 | 0.140 | – | – |
| Locoregional therapy before LT (yes, no) (51 vs. 8) | 2.90 | 0.38–21.72 | 0.299 | – | – |
| Liver transplantation | | | | | |
| Age at LT (≤55, > 55 years) (33 vs. 28) | 1.10 | 0.45–2.67 | 0.819 | – | – |
| AFP (≥200, <200 ng/ml) (11 vs. 48) | 1.09 | 0.36–3.29 | 0.869 | – | – |
| MELD score (≥20, <20) (4 vs. 55) | 0.04 | 0.01–47.7 | 0.380 | – | – |
| Child class (A, B/C) (41 vs. 18) | 0.55 | 0.23–1.35 | 0.195 | – | – |
| Type of LT (DDLT, LDLT) (12 vs. 47) | 0.75 | 0.22–2.57 | 0.650 | – | – |
| GRWR (≥0.8, <0.8%) (45 vs. 14) | 1.13 | 0.37–3.97 | 0.824 | – | – |
| Tumor number (≥3, < 3) (10 vs. 49) | 1.58 | 0.57–4.38 | 0.375 | – | – |
| Maximum tumor size (≥5, < 3 cm) (16 vs. 43) | 3.34 | 1.25–8.31 | 0.015 | 1.83 (0.52–6.45) | 0.341 |
| Histology grade (I/II, III/IV) (44 vs. 15) | 0.75 | 0.30–1.90 | 0.551 | – | – |
| Satellite nodule (yes, no) (3 vs. 56) | 1.56 | 0.36–6.76 | 0.548 | – | – |
| Microvascular invasion (yes, no) (15 vs. 44) | 1.69 | 0.66–4.32 | 0.270 | – | – |
| UCSF (beyond, within) (13 vs. 46) | 2.77 | 1.11–6.91 | 0.029 | 0.40 (0.09–6.16) | 0.199 |
| HCC recurrence after LT (yes, no) (15 vs. 44) | 5.84 | 2.29–14.85 | <0.001 | 5.45 (1.44–20.57) | 0.012 |

Abbreviations: HCC: hepatocellular carcinoma; AFP: alpha-fetoprotein; LR: liver resection; LT: liver transplantation; UCSF: University of California at San Francisco; DDLT: deceased donor liver transplantation; LDLT: living donor liver transplantation; MELD: model for end-stage liver disease; HR: hazard ratio; CI: confidence interval; GRWR: graft recipient weight ratio.

Currently, LT has been considered the best therapeutic option for patients who have liver cirrhosis associated with HCC but are ineligible for liver resection. However, HCC recurrence after LT remains a major concern that accounted for 10–20% of patients in most reports of primary LT. The importance of HCC recurrence after LT was also reflected by the present study, in which it was the solely independent risk factors affecting overall survival of patients. Therefore, prevention of HCC recurrence after LT remains a major concern.
recurrence after LT might be an important task to improve long-term outcome of patients. However, the incidence of HCC recurrence after LT in the present study might be a little higher than the majority of reports in the literature. The theoretical explanation of this phenomenon could possibly be related to host factors, in which patients who were recurrent disease perhaps had a tendency or higher risk to develop HCC recurrence again. Moreover, many studies had similar results that a relatively higher ratio of HCC recurrence in salvage LT as compared with primary LT [10,31]. Additionally, the use of locoregional therapy could probably halt tumor progression as well as down-staging HCC in patients waiting LT. Studies had also demonstrated that certain effect of locoregional therapy could diminish the risk of HCC recurrence after LT [32,33]. Nonetheless, locoregional therapy prior to LT had no significant benefit in terms of RFS in this study. The present study might be limited by its small patient number with a heterogeneous subgroup and unable to explain the observation. Apart from that, the majority of patients nearly 90% had locoregional therapy prior to LT leading to difficulty of statistical difference.

Additionally, the surgical difficulty in LT for patients who have undergone previous LR remains a great challenge despite the advancement of surgical instruments and techniques. In such circumstances, the difficulty might be related to adhesion above the liver’s surface, vigorous portal collaterals and/or extensive hilar dissection performed during previous LR. Although some studies have shown the difficulty of salvage LT neither increases postoperative complications nor negatively affects the prognosis of patients [13,34,35], a longer operative time and possibly more blood loss during the operation would come across to surgeons. Therefore, the use of bio-resorbable membranes in primary LR might be able to reduce perihepatic adhesions and decrease the surgical difficulty of salvage LT [36].

**Conclusion**

In summary, surgical management including LR and LT could be the best potential curative therapy available for patients with HCC depending on suitable clinical scenario. As such, LR followed by LT for late stage liver cirrhosis and/or recurrent HCC could be a promising strategy for patients with HCC. Although the study is limited by a small number of patients and its retrospective nature, several marked observations might be helpful in the decision-making of therapeutic options for patients with HCC. The results illustrate that tumor features at both LR and LT are likely to play potential roles affecting patient outcome, indicating that large tumor size at LR should be taken into caution tending to HCC recurrence after salvage LT. Most importantly, LT should be considered as soon as possible preferably within 1 year whenever recurrent HCC following LR meets transplantation criteria.

**Conflicts of interest**

All authors have no conflicts of interest.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j bj.2019.04.001.

**References**

[1] Bruix J, Sherman M, Practice Guidelines Committee. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.

[2] Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg 2016;263:1112–25.

[3] Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–403.

[4] Mazzaferrro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Boffetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–9.

[5] De Carli L, Giacomoni A, Pirotta V, Lauterio A, Slim AO, Sammartino C, et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg 2003;196:887–97.

[6] Figueras J, Jaunrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000;190:580–7.

[7] Chapman WC, Klintmalm G, Hemming A, Vachharajani N, Majella Doyle MB, DeMatteo R, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg 2015;220:628–37.

[8] Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. Hepatology 2000;31:899–906.

[9] Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373–82.

[10] Bhargaii P, Allard MA, Vibert E, Cherqui D, Pelletier G, Cunha AS, et al. Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg 2016;264:155–63.
[11] De Carlis L, Di Sandro S, Giacomoni A, Mangoni I, Lautiero A, Mihaylov P, et al. Liver transplantation for hepatocellular carcinoma recurrence after liver resection: why deny this chance of cure? J Clin Gastroenterol 2013;47:352–8.

[12] Fuks D, Dokmak S, Paradis V, Diouf M, Durand F, Belghiti J. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 2012;55:332–40.

[13] Lee CF, Eldeen FZ, Chan KM, Wu TH, Soong RS, Wu TJ, et al. Bortezomib is effective to treat acute humoral rejection after liver transplantation. Transplant Proc 2012;44:529–31.

[14] Chen MY, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, et al. Efficacy of external beam radiation-based treatment plus locoregional therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Biomed Res Int 2016;2016:6017406.

[15] Chan KM, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, et al. The preference for anterior approach major hepatectomy: experience over 3 decades and a propensity score-matching analysis in right hepatectomy for hepatocellular carcinoma. Medicine (Baltim) 2015;94:e1385.

[16] Lee WC, Lee CF, Cheng CH, Wu TJ, Chou HS, Wu TH, et al. Outcomes of liver resection for hepatocellular carcinoma in liver transplantation era. Eur J Surg Oncol 2015;41:1144–52.

[17] Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63–70.

[18] Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Chan KM, Lee WC, Hung CF, Yu MC, Jan YY, Chen MF. Chan KM, Chou HS, Wu TJ, Lee CF, Yu MC, Lee WC. Ann Surg 2001;234:63–70.

[19] Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502–9. Discussion 9–11.

[20] Mazzaferrro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35–43.

[21] Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, et al. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 1996;77:2022–31.

[22] Sumie S, Kurosawa S, Okuda K, Ando E, Takata A, Fukushima N, et al. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008;15:1375–82.

[23] Mehta N, Heimbach J, Lee D, Dodge JL, Harndis D, Burns J, et al. Wait time of less than 6 and greater than 18 Months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time “sweet spot”. Transplantation 2017;101:2071–8.

[24] Wang TH, Lee PC, Chiang YJ. Taiwan’s organ donation and transplantation: observation from national registry point of view. J Formos Med Assoc 2017;116:649–51.

[25] de Haas RJ, Lim C, Bhangui P, Salloum C, Compagnon P, Feray C, et al. Curative salvage liver transplantation in patients with cirrhosis and hepatocellular carcinoma: an intention-to-treat analysis. Hepatology 2018;67:204–15.

[26] Agopian VG, Harlander-Locke MP, Ruiz RM, Klintmalm GB, Senguttuvan S, Florman SS, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within milan criteria undergoing liver transplantation: analysis of 3601 patients from the US multicenter HCC transplant consortium. Ann Surg 2017;266:525–35.

[27] Chan KM, Yu MC, Chou HS, Wu TJ, Lee CF, Lee WC. Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation. Ann Surg Oncol 2011;18:2638–46.

[28] Cucchieta A, Vitale A, Del Gaudio M, Ravaiol M, Ercolani G, Cescon M, et al. Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma. Am J Transplant 2010;10:619–27.

[29] Eguchi S, Hidaka M, Tomonaga T, Miyazaki K, Inokuma T, Takatsuki M, et al. Actual therapeutic efficacy of pre transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol 2009;44:624–9.

[30] Dupre A, Lefranc A, Buc E, Delpero JR, Quenet F, Passot G, et al. Use of bioresorbable membranes to reduce abdominal and perihilar adhesions in 2-stage hepatectomy of liver metastases from colorectal cancer: results of a prospective, randomized controlled phase II trial. Ann Surg 2013;258:30–6.